Search

A new family of molecular hybrids, between cyclolignans related to podophyllic aldehyde and several diterpenylnaphthohydroquinones (DNHQ), was prepared and its biological activity evaluated in several human solid tumor cell lines, which are representative of the most prevalent solid tumors in the Western world. Both cyclolignan and quinone fragments were linked through aliphatic or aromatic spacers. The new hybrid family was evaluated for its cytotoxicity, and it was found that the hybrids were several times more potent against the osteosarcoma cell line MG-63 than against MCF-7 and HT-29 cell lines. The presence of an aromatic ring in the linker gave the most potent and selective agent, improving the cytotoxicity of the parent compounds. Cell cycle studies demonstrated that this hybrid induces a strong and rapid apoptotic effect and arrests cells at the G2/M phase of the cell cycle, in the same way that the parent compound podophyllic aldehyde does., Financial support came from Spanish MINECO (CTQ2015-68175-R, AGL2016-79813-C2-2-R), Junta de Castilla y Leon (BIO/SA07/15), and ISCIII-RICET Network (RD06/0022/1004) cofinanced by the Fondo Social Europeo of the European Union (Fondos FEDER − EU. Fundacion Solorzano (FS/23-2015) has also sponsored this work. The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by Grant No. PT13/0001, of the PE I+D+I 2013-2016, funded by ISCIII and FEDER. Á.P.H. and P.D. are supported by JCYL-EDU/ 346/2013 Ph.D. scholarships.

The immunocompability of polyelectrolyte capsules synthesized by layer-by-layer deposition has been investigated. Capsules of different architecture and composed of either non-degradable or biodegradable polymers, with either positively or negatively charged outer surface, and with micrometer size, have been used, and the capsule uptake by different cell lines has been studied and quantified. Immunocompatibility studies were performed with peripheral blood mononuclear cells (PBMCs). Data demonstrate that incubation with capsules, at concentrations relevant for practical applications, did not result in a reduced viability of cells, as it did not show an increased apoptosis. Presence of capsules also did not result in an increased expression of TNF-α, as detected with antibody staining, as well as at mRNA level. It also did not result in increased expression of IL-6, as detected at mRNA level. These results indicate that the polyelectrolyte capsules used in this study are immunocompatible., This work was supported by the German Research Foundation (DFG grant PA 794/21-1 to W.J.P.) and the Sino-German cooperative project No. GZ 905 from the Sino German Center. We gratefully acknowledge financial support from the Carlos III Health Institute of Spain (ISCIII, FIS PI14/01538), Fondos FEDER (EU), Junta Castilla-Leon BIO/SA07/15, Fundacion Solorzano FS/23-2015. The Proteomics Units belongs to ProteoRed, PRB2-ISCIII, supported by grant PT13/0001. P.D. is supported by a JCYL-EDU/346/2013 PhD scholarship. D.P. acknowledges the FTA: Nanomedicines for Personalized Theranostics of the Israeli National Nanotechnology Initiative and the Leona M. and Harry B. Helmsley Nanotechnology Research Fund. A.E. acknowledges Junta de Andalucía (Spain) for a Talentia Postdoc Fellowship, cofinanced by the European Union Seventh Framework Programme, grant agreement no 267226.

Osteoarthritis (OA) is one of the most prevalent articular diseases. The identification of proteins closely associated with the diagnosis, progression, prognosis, and treatment response is dramatically required for this pathology. In this work, differential serum protein profiles have been identified in OA and rheumatoid arthritis (RA) by antibody arrays containing 151 antibodies against 121 antigens in a cohort of 36 samples. Then the identified differential serum protein profiles have been validated in a larger cohort of 282 samples. The overall immunoreactivity is higher in the pathological situations in comparison with the controls. Several proteins have been identified as biomarker candidates for OA and RA. Most of these biomarker candidates are proteins related to inflammatory response, lipid metabolism, or bone and extracellular matrix formation, degradation, or remodeling., We gratefully acknowledge financial support from the Carlos III Health Institute of Spain (ISCIII, FIS PI14/01538, PI12/00624, PI12/00329, PI14/01707, CIBER-CB06/01/0040, and RETIC-RIER-RD12/0009/0018), Fondos FEDER (EU), Junta Castilla y Leon (BIO/SA07/15), and Fundacion Solorzano (FS-23-2015). The Proteomics Unit belongs to ProteoRed, PRB2-ISCIII, supported by Grant No. PT13/0001 (ISCIII Fondos FEDER). P.D. and C.D. are supported by a JCYL-EDU/346/2013 Ph.D. scholarship. The work of D.G.M. was supported by a collaboration scholarship (BOE-A-2014-3844) from the Spanish Ministry of Education, Culture, and Sports (MECD) and awarded in the XIII Certamen Universitario Arquimedes (BOE-A-2014-12688, MECD).

We report herein the design of a smart delivery system in which cargo delivery from capped mesoporous silica (MS) nanoparticles is controlled by an integrated enzyme-based control unit . The system consists of Janus-type nanoparticles having opposing Au and MS faces, functionalized with a pH-responsive β-cyclodextrin-based supramolecular nanovalve on the MS surface and two effectors, glucose oxidase and esterase, immobilized on the Au face. The nanodevice behaves as an enzymatic logical OR operator which is selectively fueled by the presence of D-glucose and ethyl butyrate., R.V. acknowledges a Ramon & Cajal contract from the Spanish Ministry of Science and Innovation. Financial support from the Spanish Ministry of Science and Innovation (CTQ2011-24355, CTQ2009-12650, CTQ2009-09351, MAT2012-38429-C04-01) and Comunidad de Madrid (S2009/PPQ-1642, programme AVANSENS) is gratefully acknowledged. The Generalitat Valencia (project PROMETEO/2009/016) is also acknowledged.

PMCID: PMC3539432; NIHMSID: NIHMS430346.-- et al., A first research development progress report of the Chromosome 19 Consortium with members from Sweden, Norway, Spain, United States, China and India, a part of the Chromosome-centric Human Proteome Project (C-HPP) global initiative, is presented (http://www.c-hpp.org). From the chromosome 19 peptide-targeted library constituting 6159 peptides, a pilot study was conducted using a subset with 125 isotope-labeled peptides. We applied an annotation strategy with triple quadrupole, ESI-Qtrap, and MALDI mass spectrometry platforms, comparing the quality of data within and in between these instrumental set-ups. LC-MS conditions were outlined by multiplex assay developments, followed by MRM assay developments. SRM was applied to biobank samples, quantifying kallikrein 3 (prostate specific antigen) in plasma from prostate cancer patients. The antibody production has been initiated for more than 1200 genes from the entire chromosome 19, and the progress developments are presented. We developed a dedicated transcript microarray to serve as the mRNA identifier by screening cancer cell lines. NAPPA protein arrays were built to align with the transcript data with the Chromosome 19 NAPPA chip, dedicated to 90 proteins, as the first development delivery. We have introduced an IT-infrastructure utilizing a LIMS system that serves as the key interface for the research teams to share and explore data generated within the project. The cross-site data repository will form the basis for sample processing, including biological samples as well as patient samples from national Biobanks. © 2012 American Chemical Society., This work was supported by grants from the Swedish Academy of Pharmaceutical Sciences who is the core founder our consortium, Swedish Research Council, the Swedish Foundation for Strategic Research, Vinnova, Ingabritt & Arne Lundbergs forskningsstiftelse, the Crafoord Foundation and by Thermo Fisher Scientific for mass spectrometry instrument support. T.E.F. is supported by the Mobilitas Program sponsored by the European Union Social Fund and administered by the Estonian Science Foundation. We gratefully acknowledge financial support to M.F. from Health Institute Carlos III of Spain (ISCIII, FIS PI02114) and M.G.-G. is supported by a PhD scholarship of ISCIII FI08/00721. C.L.N. is supported by the Cancer Prevention and Research Institute of Texas and the University of Texas Medical Branch. [11-0624]; National Cancer Institute [R33 CA 127768-03, R01CA160816, and P50-CA92629]; Sidney Kimmel Center for Prostate and Urologic Cancers; and David H. Koch through the Prostate Cancer Foundation.